Physician profile
Casey Parker
NPI 1144098062
$1,887.36
in general payments reported to CMS, 2019-2025
17 companies · $1,194 in 2025
The $1,194 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $693 · 2025: $1,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,887.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $583.04 | 2024-2025 | Tremfya, Stelara |
| Pfizer INC. | $214.55 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $201.16 | 2024-2025 | Entyvio, Eohilia |
| Depuy Synthes Sales INC. | $165.49 | 2025 | Va-Lcp, Multiloc, Na |
| Madrigal Pharmaceuticals | $123.19 | 2024-2025 | Resmetirom, Rezdiffra |
| Mallinckrodt Hospital Products INC. | $113.51 | 2025 | Terlivaz |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.24 | 2024-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $79.34 | 2024-2025 | Dupixent |
| Ardelyx, INC. | $68.28 | 2024-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $58.05 | 2025 | Iqirvo |
| Abbvie INC. | $45.75 | 2025 | |
| Lilly USA, LLC | $40.48 | 2024 | Omvoh |
| Phathom Pharmaceuticals, INC. | $32.90 | 2024-2025 | Voquezna |
| Pharmacosmos Therapeutics INC. | $27.11 | 2024 | Monoferric |
| Genzyme Corporation | $18.98 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $18.47 | 2025 | Sucraid |
| Novo Nordisk INC | $13.82 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.